465 related articles for article (PubMed ID: 19238094)
21. Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective.
Carter JA; Huang X; Jamil K; Corman S; Ektare V; Niewoehner J
J Med Econ; 2023; 26(1):1342-1348. PubMed ID: 37729445
[TBL] [Abstract][Full Text] [Related]
22. Limited Progress in Hepatorenal Syndrome (HRS) Reversal and Survival 2002-2018: A Systematic Review and Meta-Analysis.
Thomson MJ; Taylor A; Sharma P; Lok AS; Tapper EB
Dig Dis Sci; 2020 May; 65(5):1539-1548. PubMed ID: 31571102
[TBL] [Abstract][Full Text] [Related]
23. [Hepatorenal syndrome: a new therapeutic approach?].
Gerbes AL; Gülberg V
Z Gastroenterol; 1999 Sep; 37(9):983-5. PubMed ID: 10522370
[No Abstract] [Full Text] [Related]
24. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study.
Péron JM; Bureau C; Gonzalez L; Garcia-Ricard F; de Soyres O; Dupuis E; Alric L; Pourrat J; Vinel JP
Am J Gastroenterol; 2005 Dec; 100(12):2702-7. PubMed ID: 16393223
[TBL] [Abstract][Full Text] [Related]
25. Standardized approach of albumin, midodrine and octreotide on hepatorenal syndrome treatment response rate.
Hiruy A; Nelson J; Zori A; Morelli G; Cabrera R; Kamel A
Eur J Gastroenterol Hepatol; 2021 Jan; 33(1):102-106. PubMed ID: 32243349
[TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.
Facciorusso A; Chandar AK; Murad MH; Prokop LJ; Muscatiello N; Kamath PS; Singh S
Lancet Gastroenterol Hepatol; 2017 Feb; 2(2):94-102. PubMed ID: 28403995
[TBL] [Abstract][Full Text] [Related]
27. Targeting an early and substantial increase in mean arterial pressure is critical in the management of type 1 hepatorenal syndrome: a combined retrospective and pilot study.
Maddukuri G; Cai CX; Munigala S; Mohammadi F; Zhang Z
Dig Dis Sci; 2014 Feb; 59(2):471-81. PubMed ID: 24146317
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological Therapies for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis.
Nanda A; Reddy R; Safraz H; Salameh H; Singal AK
J Clin Gastroenterol; 2018 Apr; 52(4):360-367. PubMed ID: 28991106
[TBL] [Abstract][Full Text] [Related]
29. Management and outcome in hepatorenal syndrome: need for renal replacement therapy in non-transplanted patients.
Sourianarayanane A; Raina R; Garg G; McCullough AJ; O'Shea RS
Int Urol Nephrol; 2014 Apr; 46(4):793-800. PubMed ID: 23934619
[TBL] [Abstract][Full Text] [Related]
30. Review article: pharmacological treatment of hepatorenal syndrome.
Ginès P; Torre A; Terra C; Guevara M
Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():57-62; discussion 63-4. PubMed ID: 15335404
[TBL] [Abstract][Full Text] [Related]
31. Treatment of Type-1 Hepatorenal Syndrome with Pentoxifylline: A Randomized Placebo Controlled Clinical Trial.
Stine JG; Wang J; Cornella SL; Behm BW; Henry Z; Shah NL; Caldwell SH; Northup PG
Ann Hepatol; 2018 Mar; 17(2):300-306. PubMed ID: 29469046
[TBL] [Abstract][Full Text] [Related]
32. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine.
Gülberg V; Bilzer M; Gerbes AL
Hepatology; 1999 Oct; 30(4):870-5. PubMed ID: 10498636
[TBL] [Abstract][Full Text] [Related]
33. Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study.
von Kalckreuth V; Glowa F; Geibler M; Lohse AW; Denzer UW
Z Gastroenterol; 2009 Jan; 47(1):21-6. PubMed ID: 19156588
[TBL] [Abstract][Full Text] [Related]
34. Terlipressin therapy for renal failure in cirrhosis.
Triantos CK; Samonakis D; Thalheimer U; Cholongitas E; Senzolo M; Marelli L; Leandro G; Patch D; Burroughs AK
Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):481-6. PubMed ID: 19952764
[TBL] [Abstract][Full Text] [Related]
35. Possible increased risk of pulmonary edema in patients with hepatorenal syndrome on adding octreotide to albumin / noradrenaline therapies.
Abutaleb N
Saudi J Kidney Dis Transpl; 2007 Jun; 18(2):261. PubMed ID: 17496406
[No Abstract] [Full Text] [Related]
36. The hepatorenal syndrome in liver transplant recipients.
Seu P; Wilkinson AH; Shaked A; Busuttil RW
Am Surg; 1991 Dec; 57(12):806-9. PubMed ID: 1746799
[TBL] [Abstract][Full Text] [Related]
37. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
Sharma P; Kumar A; Shrama BC; Sarin SK
Am J Gastroenterol; 2008 Jul; 103(7):1689-97. PubMed ID: 18557715
[TBL] [Abstract][Full Text] [Related]
38. Beneficial haemodynamic and renal sodium handling effects of combined midodrine and octreotide treatment in a cirrhotic patient with large hepatic hydrothorax and mild ascites.
Kalambokis G; Fotopoulos A; Economou M; Tsianos EV
Nephrol Dial Transplant; 2005 Nov; 20(11):2583. PubMed ID: 16105868
[No Abstract] [Full Text] [Related]
39. Review article: prognosis of hepatorenal syndrome--has it changed with current practice?
Angeli P
Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():44-6; discussion 47-8. PubMed ID: 15335400
[TBL] [Abstract][Full Text] [Related]
40. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.
Sagi SV; Mittal S; Kasturi KS; Sood GK
J Gastroenterol Hepatol; 2010 May; 25(5):880-5. PubMed ID: 20074149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
